---
title: "Cabaletta Bio | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286404901.md"
datetime: "2026-05-14T11:08:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286404901.md)
  - [en](https://longbridge.com/en/news/286404901.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286404901.md)
---

# Cabaletta Bio | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.39, beating the estimate of USD -0.4.

EBIT: As of FY2026 Q1, the actual value is USD -44.74 M.

### First Quarter 2026 Financial Results

#### Operating Expenses

-   Research and development expenses for Cabaletta Bio, Inc. were $37.4 million for the three months ended March 31, 2026, an increase from $29.0 million for the same period in 2025.
-   General and administrative expenses were $6.9 million for the three months ended March 31, 2026, a decrease from $8.1 million for the same period in 2025.
-   Total operating expenses amounted to $44.3 million for the first quarter of 2026, compared to $37.1 million for the first quarter of 2025.

#### Profitability

-   Loss from operations was -$44.3 million for the three months ended March 31, 2026, compared to -$37.1 million for the same period in 2025.
-   Interest income was $1.1 million for the first quarter of 2026, a decrease from $1.5 million in the first quarter of 2025.
-   Interest expense was -$0.6 million for the first quarter of 2026, compared to -$0.3 million for the first quarter of 2025.
-   Other income, net was $0.3 million for the first quarter of 2026, with no reported amount for the same period in 2025.
-   The net loss for the three months ended March 31, 2026, was -$43.5 million, compared to -$35.9 million for the same period in 2025.

#### Balance Sheet Data

-   Cash, cash equivalents and short-term investments for Cabaletta Bio, Inc. were $116.6 million as of March 31, 2026, down from $133.6 million as of December 31, 2025.
-   Total assets were $148.1 million as of March 31, 2026, compared to $165.1 million as of December 31, 2025.
-   Total liabilities were $44.8 million as of March 31, 2026, a decrease from $53.0 million as of December 31, 2025.
-   Total stockholders’ equity was $103.3 million as of March 31, 2026, compared to $112.1 million as of December 31, 2025.

#### Capital Activities

-   In May 2026, Cabaletta Bio, Inc. closed an underwritten registered direct offering, raising approximately $150 million in gross proceeds.

#### Outlook / Guidance

Cabaletta Bio, Inc. expects its cash position as of March 31, 2026, combined with the cash from the May 2026 registered direct offering, to fund its operating plan into mid-2027. The company anticipates its first Biologics License Application (BLA) submission for rese-cel in myositis in 2027, supported by data from the registrational RESET-Myositis trial. Cabaletta Bio, Inc. also plans to announce a second pivotal indication after presenting complete Phase 1⁄2 lupus and scleroderma data during the June 2026 EULAR Congress, and expects to report longer-term, PC-free rese-cel data in the second half of 2026.

### Related Stocks

- [CABA.US](https://longbridge.com/en/quote/CABA.US.md)

## Related News & Research

- [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | CABA Stock News](https://longbridge.com/en/news/286404329.md)
- [Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts](https://longbridge.com/en/news/286456613.md)
- [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)
- [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)